When the Bush administration came in and Todd Dickinson left his post as director of the US Patent and Trademark Office, there were approximately 10,000 outstanding gene-based patent applications. Early patents of this type tended to be full-length sequences; now, most focus on ESTs or SNPs. Since April, Dickinson hangs his shingle at the law firm Howrey Simon Arnold and White, where he’s a partner dealing with IP. GT’s Meredith Salisbury caught up with him to find out about guidelines, evaluations, and patent pooling.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.